EKF Diagnostics Investor Announcements
EKF Diagnostics Holdings plc is an in-vitro diagnostics (IVD) business. The Company is engaged in the designing, development, manufacture and selling of diagnostic analyzers, reagents and ancillary products. This activity takes place across several geographical locations which include the United Kingdom, United States of America, Germany, Poland and Russia.
Renalytix AI PLC to develop Artificial Intelligence for early identification and management of kidney disease.
Standard form for notification of major holdings.
Further announcement regarding the exclusive license and collaboration agreement with Icahn School of Medicine at Mount Sinai in New York, USA.
Renalytix AI plc to develop Artificial Intelligence for early identification and management of kidney disease.
Annual Report and Accounts for the year ended 31 December 2017 now available.
EKF announces US Food and Drug Administration 510(k) clearance and CLIA waiver for DiaSpect Tm.
Notification of major holdings.
EKF Diagnostics announces its final results for the year ended 31 December 2017.
EKF Diagnostics announces that it will release its preliminary results for the year ended 31 December 2017 on Wednesday 14 March 2018.